Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Aspira Women’s Health ( (AWHL) ).
On June 11, 2025, Aspira Women’s Health announced the termination of its contract with the Advanced Research Projects Agency for Health (ARPA-H) for the Sprint for Women’s Health initiative. Despite receiving $3.5 million of the $10 million award, ARPA-H determined that Aspira did not meet the specifications of Milestone 3, leading to the contract’s termination. Aspira’s CEO expressed confidence in the company’s progress and commitment to continue developing the ENDOinform test, which aims to improve the diagnosis and treatment of endometriosis, with a target completion in 2026.
The most recent analyst rating on (AWHL) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.
Spark’s Take on AWHL Stock
According to Spark, TipRanks’ AI Analyst, AWHL is a Neutral.
The overall stock score for Aspira Women’s Health is primarily impacted by its poor financial performance, characterized by negative equity and cash flow deficits. While the technical indicators show some short-term bullish momentum, the stock’s overbought signals and low valuation due to negative earnings suggest caution. The absence of a dividend yield further detracts from its investment appeal.
To see Spark’s full report on AWHL stock, click here.
More about Aspira Women’s Health
Aspira Women’s Health Inc. is a company dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. It offers products like OvaWatch and Ova1Plus, which are part of the OvaSuite portfolio, providing blood tests to assess ovarian cancer risk. The company is also developing non-invasive diagnostics for endometriosis, aiming to enhance the sensitivity and specificity of its current tests.
Average Trading Volume: 1,422,170
Technical Sentiment Signal: Sell
Current Market Cap: $4M
See more data about AWHL stock on TipRanks’ Stock Analysis page.